Nykode Therapeutics AS
5VB
Company Profile
Business description
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need. It operates in United States of America.
Contact
Gaustadalleen 21
Oslo Research Park
Oslo0349
NORT: +47 22958193
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.
stocks
Unconventional wisdom: A modern day bank run
Is the economy and investor portfolios at risk from a potential ‘bank run’ in private credit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,839.10 | 26.30 | 0.30% |
| CAC 40 | 7,985.08 | 0.64 | 0.01% |
| DAX 40 | 23,637.61 | 47.96 | 0.20% |
| Dow JONES (US) | 46,677.85 | 739.42 | -1.56% |
| FTSE 100 | 10,328.16 | 23.01 | 0.22% |
| HKSE | 25,465.60 | 251.16 | -0.98% |
| NASDAQ | 22,311.98 | 404.16 | -1.78% |
| Nikkei 225 | 53,819.61 | 633.35 | -1.16% |
| NZX 50 Index | 13,187.34 | 11.95 | -0.09% |
| S&P 500 | 6,672.62 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,617.10 | 29.20 | 0.34% |
| SSE Composite Index | 4,095.45 | 33.65 | -0.82% |